{"abdominal abscess": 24.29, "abnormal behaviour": 3.76, "acute kidney injury": 2.81, "acute lymphocytic leukaemia": 19.07, "acute myeloid leukaemia": 4.99, "acute respiratory distress syndrome": 5.03, "agranulocytosis": 3.04, "anaemia": 2.85, "brain oedema": 5.04, "bronchopulmonary aspergillosis": 8.67, "candida infection": 7.73, "cardiac failure": 2.0, "cardiogenic shock": 5.23, "clostridium difficile infection": 5.68, "cytomegalovirus infection": 4.22, "cytomegalovirus infection reactivation": 17.47, "cytopenia": 15.03, "disease progression": 5.58, "drug eruption": 3.41, "drug ineffective": 2.39, "drug ineffective for unapproved indication": 6.47, "drug intolerance": 2.75, "drug reaction with eosinophilia and systemic symptoms": 4.65, "drug resistance": 5.06, "enterococcal infection": 25.67, "febrile neutropenia": 8.71, "haematotoxicity": 7.0, "hepatitis b reactivation": 15.53, "hypercalcaemia": 9.17, "hypogammaglobulinaemia": 15.12, "hypokalaemia": 2.4, "hypoxia": 2.05, "ileus paralytic": 16.84, "infection": 4.73, "infusion related reaction": 4.23, "intentional product misuse": 2.72, "intentional product use issue": 2.8, "klebsiella infection": 26.72, "leukopenia": 3.11, "lower respiratory tract infection": 2.47, "lymphopenia": 5.67, "malignant neoplasm progression": 2.05, "metapneumovirus infection": 101.34, "mucosal inflammation": 8.08, "multiple organ dysfunction syndrome": 3.78, "myelodysplastic syndrome": 8.98, "myelosuppression": 6.8, "neuropathy peripheral": 17.96, "neurotoxicity": 5.75, "neutropenia": 6.69, "neutrophil count decreased": 2.19, "off label use": 3.4, "pancytopenia": 6.6, "paranoia": 7.52, "peripheral sensory neuropathy": 44.3, "plasma cell leukaemia": 219.6, "plasma cell myeloma": 140.86, "plasma cell myeloma recurrent": 169.46, "plasma cell myeloma refractory": 388.58, "plasmacytoma": 137.14, "platelet count decreased": 2.97, "pneumonia": 3.55, "polyneuropathy": 26.64, "polyomavirus-associated nephropathy": 39.73, "posterior reversible encephalopathy syndrome": 18.43, "product use in unapproved indication": 5.02, "progressive multifocal leukoencephalopathy": 14.46, "pulmonary oedema": 2.81, "renal impairment": 2.11, "respiratory failure": 2.62, "respiratory tract infection": 3.92, "sepsis": 5.87, "septic shock": 4.85, "shock": 3.5, "staphylococcal bacteraemia": 28.12, "staphylococcal sepsis": 18.25, "therapeutic product effect incomplete": 6.32, "therapeutic response decreased": 6.76, "therapy non-responder": 10.88, "therapy partial responder": 20.5, "thrombocytopenia": 7.81, "thrombotic microangiopathy": 13.13, "treatment failure": 5.41, "tumour lysis syndrome": 21.9, "vascular device infection": 17.57, "white blood cell count decreased": 2.31}